|
Table of Contents
Director’s Message
Staff Profiles
Program Description
Program Information
Guidelines for Application
Preceptorships
Post-Fellowship Employment
Life Outside the NCI
|
2007 Application Catalog
Preceptorships - Division of Cancer Prevention
Organ Systems Research Groups
The primary mission of the Gastrointestinal and Other Cancer Research Group is to improve the public’s health by preventing gastrointestinal, dermatologic, endocrine, hematolymphoid, and treatment-induced malignancies. Staff collaborate with the public, academia, industry, and regulatory agencies to better identify persons at risk for cancer and to develop novel interventions that reverse or retard carcinogenesis. The Group investigates mechanisms of promising investigational agents and delivery systems that target preneoplasia.
Chief: Jaye Viner, M.D.
Potential Preceptor:
Ernest Hawk, M.D.*, M.P.H., Jaye Viner, M.D.
Investigate mechanistic improvements of promising investigational agents and delivery systems that target preneoplasia.
- Improve risk assessment of cohorts with germline defects (e.g., familial adenomatous polyposis, HNPCC, dysplastic nevus syndrome) or somatic alterations placing them at risk for cancer.
- Investigate, apply, evaluate, and validate intermediate biomarkers for their potential as reliable predictors of advanced neoplasia or outcomes of clinical significance.
- Identify and evaluate agents (e.g., pharmacologic, biologics/vaccines, gene-based, nutritional) that interrupt or retard clinical carcinogenic progression.
- Collaborate with a multidisciplinary team of basic scientists, clinicians, statisticians, clinical researchers, and industry to design, develop, implement, and monitor Phase I, II, and III trials for investigational preventive agents.
- Design, implement, and participate in clinical prevention trials on the NIH campus with intramural collaborators.
Asad Umar, D.V.M., Ph.D.
Chemopreventive Intervention through Molecular Targeting: Novel agents that modify PI3K, AKT and IGF pathway, as well as intervention via epigenetic modulation (butyrate derived) and clinical intervention response variable analysis.
- In vitro and preclinical testing of novel agents for chemoprevention prior to clinical studies.
- Modifiers of celecoxib in Familial Adenomatous Polyposis (FAP) and Hereditary Non-polyposis Colorectal Carcinoma (HNPCC).
- In vitro validation of expression profiles (cDNA and proteomics) and their significance.
- Development of a comprehensive cross sectional profile of colorectal carcinoma (Normal> aberrant crypts >dysplasia>adenoma>carcinoma) from clinical observation (hi-res endoscopy, histopathology, tissue arrays, mutation analysis, epigenetic analysis, expression and proteomic profiles).
* Former Cancer Prevention Fellow
|
